ArticleCell death discovery2026
Immunoregulatory role of quercetin in lung cancer.
Article in Cell death discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long-term nourishment with quercetin, a naturally occurring plant flavonoid abundant in citrus fruits, buckwheat, and onions, has been associated with reduced risks of chronic diseases, including cancer. In this study, we evaluated the therapeutic potential and the anti-cancer properties of quercetin in lung cancer using in vitro, in vivo, and ex vivo models. Quercetin induced tumor cell cycle arrest via the p53-p21 axis and suppressed tumor cell migration in both the A549 and H520 human lung cancer cell lines. Moreover, it reduced oxidative stress and downregulated the protein expression of oncogenic markers such as EGFR and PD-L1 on the surface of A549 cells in a dose-response manner. Quercetin significantly attenuated the proliferation and migration of the tumor cells. In an in vivo model, quercetin decreased the tumor load without affecting the body weight. In the ex vivo model, quercetin treatment resulted in the induction of interferon alpha-2 (IFN-α2), a well-known anti-tumor cytokine. These findings demonstrate that quercetin exerts potent anti-tumoral and anti- inflammatory effects in lung cancer by regulating cell cycle, oxidative stress, and immune pathways. Overview of quercetin-induced cellular modulation in lung cancer [Created in BioRender] Quercetin had a direct effect on the tumor cell cycle, where it upregulated CDKN1A and downregulated CDK1 in both murine models and human lung cancer cell lines. Quercetin regulated the p53-p21 axis, decreased EGFR, PD-L1, and Ki67 expression, and also showed a strong inhibitory effect on tumor cell migration. It also conditioned the gut microbiome, promoting an increased abundance of SCFA-producing bacteria. At the same time, it led to an increase in IFN-α2 cytokine production. Quercetin also reprogrammed the splenic CD8 + T cell transcriptome, most notably by upregulating the tumor suppressor gene Ltf while also downregulating several oncogenes involved in proliferation and metastasis, namely POU6F1, Celsr1, ST3GAL6, Sik2, Adnp, and Jun.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.